SimonMed, one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States, announced its implementation of SyntheticMR SyMRI software to support enhanced lesion detection and allow for quantitative MRI including the tracking of myelin development in pediatric patients and patients with Multiple Sclerosis at many of its imaging sites in North America.
“The quantification of myelin through SyntheticMR is an example of our rapid progress beyond 3T MRI to use the latest MR technology to further improve diagnoses,” says John Simon, MD, chief executive of SimonMed. “I expect the partnership with SyntheticMR will yield many new technologies that will quickly improve patient care.”
“SyntheticMR is excited to partner with SimonMed,” says Kyle Frye, president, SyntheticMR Inc. “Dr. Simon and his team understand the value of continuously offering patients and their referring providers best in class technology that has the patients experience at the forefront of what they do. SimonMed will be utilizing our tissue segmentation and myelin quantification across multiple sites and states, allowing for a truly integrated solution.”
For more information, visit SyntheticMR.